More than a million coronavirus vaccine bookings were made on the NHS website yesterday - a record total. The NHS chief executive compares the demand, on the first day all 25 to 2 ...

The virus often mutates by simply deleting small pieces of its genetic code. The mutations "disguise" the virus from antibodies.

Severe COVID-19 raises lung cancer risk by 24%, study of 76 million Americans finds In A Nutshell People hospitalized with severe COVID-19 had roughly a 24 percent higher risk of developing lung ...

The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical trial stages, the first COVID-19 mRNA vaccine was administered on 8 December ...

A recent experimental treatment may offer a new method to prevent HIV infection: by combining two antiviral tactics into a single antibody. In laboratory studies, the new molecule forced the virus to ...

Machine learning reveals unique COVID vaccine immune signatures in people living with HIV, with differences in antibodies, cytokines, and T cell responses.

The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical trial stages, the first COVID-19 mRNA vaccine was administered on 8 December ...

The move comes as BioNTech shifts to being a multiproduct commercial biotech, allowing Ugur Sahin and Özlem Türeci to transition back into research on next-generation mRNA therapeutics.

The co-founders of the Covid-19 vaccine developer BioNTech plan to leave the biotech to start a new mRNA-focused company ...

BioNTech’s CEO and his fellow co-founder will depart the biopharma by the end of the year to head up a new company focused on “next generation mRNA innovations.” Uğur Şahin, M.D., who is currently the ...

Cas9, Transcription Activator-Like Effector Nucleases (TALENs), and Zinc-Finger nucleases (ZFNs) have demonstrated great utility, primarily for genetic knock-out applications, none have been adopted ...

Independently developed by Junshi Biosciences, JS001sc injection is a subcutaneous injection based on the marketed product toripalimab injection (code: JS001) that is expected to enhance convenience ...